TerminatedPhase 3NCT05676853

A Study of Safety of Weekly Subcutaneous Pegzilarginase in Subjects With Arginase 1 Deficiency

Studying Argininemia

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Aeglea Biotherapeutics
Principal Investigator: Cortney Caudill, LCSW
Aeglea BioTherapeutics, Inc.
Intervention: Pegzilarginase(drug)
Enrollment: 3 enrolled
Eligibility: All sexes
Timeline: 2023 – 2023

Study locations (1)

Hospital for Sick Children, Toronto, Ontario, Canada

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05676853 on ClinicalTrials.gov

← Back to all trials